India Pharma Outlook Team | Monday, 16 February 2026
Natco Pharma shares surged sharply on Monday after the company secured regulatory approval to manufacture and market a key diabetes drug in India, triggering heavy buying on the bourses.
The stock of the Hyderabas based drug company rose up to 10.95 to a high of 914.95 on the National Stock Exchange. The share surged up 11.2 percent on the BSE to an intraday high of ?914.25 with a sharp rise in the trading volumes.
The stock market rebounded the previous weekend after the company announced it had received Semaglutide approval in India by the Central Drugs Standard Control Organisation.
Also Read: Containment Strategies in Pharma Facilities
"Natco Pharma("NATCO") received approval for Semaglutide from CDSCO to manufacture and market generic Semaglutide Injection in India. NATCO will launch the product in the India market in March’26," the Hyderabad-based drug maker said in a regulatory filing.
Semaglutide is a medication used in adults suffering type 2 diabetes that has not been controlled well enough, with diet and physical activity.
The volumes showed interest by investors. The NSE trading increased 6.4 times to 43.91 lakh shares on average 6.83 lakh shares. At the BSE, there was a total 3.29 lakh shares traded against the two-week average of the shares was 41,000 shares per day.
Natco Pharma stocks were up 10.76 percent higher at 10:06 am at ?912 as compared to the NIFTY Smallcap 100 index that fell 0.1 percent.
The stock market has also surged days following the announcement of the company that consolidated net profit has increased by 14 per cent year-on-year to 151 crore in the December quarter, whereas revenue has risen to 647 crore against 475 crore in the previous quarter.
